Medicine
Ruxience 100 mg/10 mL injection
Ruxience 100 mg/10 mL injection is a prescription medicine containing Rituximab for intravenous use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store RUXIENCE vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Rituximab
- Brand
- Ruxience
- Strength
- 100 mg/10 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 10 mL
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Store RUXIENCE vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Do not freeze or shake. RUXIENCE vials should be protected from direct sunlight.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01FA01 Rituximab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 January 2020
- Identifiers
- RxCUI 2273512, 2273517, 2273520 +1DailyMed set ID f941fc61-f7a3-4e4a-ab7c-87c1667fa05bNDC 0069-0238Application BLA761103
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 10 mL in 1 vial, single-use | 0069-0238-01 | Pfizer Laboratories | 23 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Rituximab 100 mg/10 mL injection.
Other strengths and forms of Rituximab
Clinical summary
Rituximab is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Rituximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RituximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Rituxan prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- MabThera: European public assessment report (EPAR) · European Medicines Agency
- Blitzima: European public assessment report (EPAR) · European Medicines Agency
Need Ruxience 100 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.